Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 821 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Genotype Clear all
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System

NCT01694875
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
APTIMA HPV Assay
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
21 Years and older · Female only
Enrollment
2,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Minneapolis, Minnesota • Burlington, North Carolina • Maryville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 4 Interventional Results available

Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism

NCT00920829
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Naltrexone 50 Mg, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease

NCT03036839
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

NCT02114177
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 18, 2026, 3:27 AM EDT
Completed No phase listed Observational

Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients

NCT04148001
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
Not listed
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation

NCT00135798
View directory record Official record
Conditions
Hepatitis C
Interventions
LADR Treatment
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 18, 2026, 3:27 AM EDT
Terminated No phase listed Observational Results available

Pharmacogenomics for Antidepressant Guidance and Education

NCT01555021
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Genotyping assays
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 18, 2026, 3:27 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Recall by Genotype: Neuropeptide Stimulation

NCT05901467
View directory record Official record
Conditions
Reproductive Disorder
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated interferon alfa 2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 18, 2026, 3:27 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

NCT06510699
View directory record Official record
Conditions
Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
Interventions
genotype-directed dosing with dosing software based on therapeutic drug monitoring
Other
Lead sponsor
The University of Queensland
Other
Eligibility
2 Years and older
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis

NCT02639338
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
30
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 18, 2026, 3:27 AM EDT
Active, not recruiting No phase listed Observational

Prospective Collection of Whole Blood Specimens From RhD Negative Pregnant Women

NCT06690099
View directory record Official record
Conditions
Rhesus D Genotype, Pregnancy
Interventions
Not listed
Lead sponsor
Devyser Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 2 Interventional

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

NCT03636347
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
Interventions
Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensitive Periods in Early Flavor Learning

NCT00994747
View directory record Official record
Conditions
Healthy
Interventions
Nutramigen (Flavor and Type of Infant Formula), Enfamil, milk-based formula
Other
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
2 Weeks to 4 Weeks
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 18, 2026, 3:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Screening Strategies Among High-risk Populations for Anal Cancer

NCT06628570
View directory record Official record
Conditions
Neoplasms, HPV-Related Anal Squamous Cell Carcinoma
Interventions
HRA + Biopsy, Anal Cytology, Genotyping of anal hrHPV infection, CINtec®PLUS
Diagnostic Test
Lead sponsor
Lisa Flowers
Other
Eligibility
30 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
4
States / cities
Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Completed No phase listed Observational

Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral Therapy

NCT00009256
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 3:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Personalized Environment and Genes Study

NCT00341237
View directory record Official record
Conditions
Diabetes, Heart Disease, Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

NCT01447394
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Pegylated Interferon Lambda, Pegylated Interferon Alfa-2a, Ribavirin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
San Diego, California • Rochester, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Sofosbuvir and Ribavirin

NCT01497366
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Birmingham, Alabama • Montgomery, Alabama • Bakersfield, California + 55 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 18, 2026, 3:27 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection

NCT02378961
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 18, 2026, 3:27 AM EDT
Not yet recruiting Not applicable Interventional

Precision Nutrition for Obesity and Prediabetes Prevention in Under-supported Communities

NCT07850531
View directory record Official record
Conditions
Obesity & Overweight, Prediabetes
Interventions
Precision Nutrition Intervention, Standard Nutrition Counseling
Behavioral
Lead sponsor
Prairie View A&M University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Prairie View, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Recruiting No phase listed Observational

Drug-Induced Liver Injury (DILI) Network Retrospective

NCT00360646
View directory record Official record
Conditions
Drug Induced Liver Injury
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
2 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 18, 2026, 3:27 AM EDT
Not listed No phase listed Observational

Association Between a Multi-Gene Panel and Renal Denervation Effectiveness in Patients With Hypertension

NCT04060641
View directory record Official record
Conditions
Hypertension
Interventions
Geneticure for RDN Genetic Panel
Genetic
Lead sponsor
Geneticure, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 18, 2026, 3:27 AM EDT
Active, not recruiting No phase listed Observational

Precision PCI Registry

NCT06143709
View directory record Official record
Conditions
Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
DNA sample collection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 3:27 AM EDT